Comparison · NCT02639182-d12e0f70
AGS-16C3F vs Axitinib: Number of Participants With Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AGS-16C3F vs Axitinib: Number of Participants With Adverse Events. Trial comparisons, record NCT02639182-d12e0f70. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02639182-d12e0f70
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.985 | 0.919 | 0.997 | wilson | |
| Risk in group 2 | 0.985 | 0.918 | 0.997 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000233 | -0.0668 | 0.0681 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.958 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.0622 | 16.6 | log | |
| Number needed to treat, for one more participant with the outcome on AGS-16C3F than on Axitinib | 4,290 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AGS-16C3F | Participants received 1.8 mg/kg of AGS-16C3F once every three weeks by single (60-minute) IV infusion. | 65 | 66 | OG000 |
| Group 2 | Axitinib | Participants received axitinib at a starting dose of 5 mg orally twice daily and then adjusted to 2 to 10 mg orally twice daily, as defined in the product label and per local institutional guidelines. | 64 | 65 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Adverse Events
- Description
AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, ECG data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator. AE was considered serious if it results in death or is life threatening results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions or results in congenital anomaly, or birth defect requires inpatient hospitalization or leads to prolongation of hospitalization or other medically important events.
- Time frame
- From first dose up to 53 months
- Population
- Safety Population: All randomized participants who received at least one dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- NCT number
- NCT02639182
- Phases
- PHASE2
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- AGS-16C3F, Axitinib
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Results first posted
- 2020-09-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02639182?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02639182-d12e0f70